This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. STAT is also producing a free pop-up newsletter about this year’s ASCO meeting. Sign up here.
Chicago, here I come. The annual meeting of the American Society of Clinical Oncology kicks off tomorrow and runs through Tuesday, June 2.
Let’s set the table for cancer research’s big event, starting with the obvious headliner: Revolution Medicines and its RAS-blocking pancreatic cancer drug daraxonrasib. Full results from the company’s Phase 3 RASolute 302 study will feature prominently at ASCO’s plenary session on Sunday afternoon. The arena-sized exhibition hall will be jam-packed.
We already have the strongly positive topline results in hand from RevMed’s April press release: Patients with advanced pancreatic cancer who received daraxonrasib as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months for patients offered standard chemotherapy.
Statistically, daraxonrasib reduced the risk of death by 60% compared with chemotherapy — an impressive result for a highly lethal cancer that had proved stubbornly resistant to targeted drugs and immunotherapy. Until now.
